20 June 2012
Pulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH
Mehandar Kumar, Vanessa Mae Abrina, Sasikala ChittimireddyDOI: 10.12659/AJCR.883107
Am J Case Rep 2012; 13:118-121
Abstract
Background: Heparin induced thrombocytopenia (HIT) is a serious complication associated with heparin use. HIT usually develops between 5–14 days after starting heparin. Delayed-onset HIT can still occur 9–45 days after heparin had been discontinued. In patients with delayed HIT, the patient might be admitted to the hospital for new thrombosis and reexposure to heparin further worsens the patient’s condition.
Case Report: Our patient is a 71-year old female readmitted for worsening dyspnea 2 weeks after she was discharged from the hospital. On her previous hospitalization, she was diagnosed with bronchiolitis obliterans organizing pneumonia (BOOP). She had received prophylactic doses of LMWH. Dyspnea was initially thought to be secondary to CHF exacerbation secondary to atrial fibrillation with rapid ventricular response. She was started on a heparin. However, the patient’s clinical condition deteriorated and she needed to be intubated. Her platelet counts also decreased rapidly. After CT angiography of the chest showed pulmonary embolism, HIT was strongly considered. All forms of heparin were discontinued and argatroban was started. However, the patient did not improve and she subsequently expired on the 7th hospital day. Heparin-induced antibodies came back positive that same day.
Conclusions: HIT is an immune-mediated disorder characterized by formation of antibodies against heparin-platelet factor 4 complex. The major clinical presentation of HIT is arterial and venous thrombosis. Once HIT is suspected, immediate cessation of any form of heparin is needed. Alternative anticoagulation must be started. Early treatment decreases the incidence of new thrombosis and stroke, and improves survival and cost savings.
Keywords: heparin induced thrombocytopenia, Thrombosis, Argatroban, leupridin.
SARS-CoV-2/COVID-19
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936574
In Press
23 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935148
23 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936704
23 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936600
20 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
19 Feb 2022 : Case report
DOI :10.12659/AJCR.935355
Am J Case Rep 2022; 23:e935355